SCHEMBL5722147

SCHEMBL5722147

C1=NC=c2ncc3c(c21)-c1ccccc1N=3

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512605 0.75
SCHEMBL27847849 0.67
SCHEMBL7225836 0.66
SCHEMBL3241529 0.66
SCHEMBL4512756 0.66
SCHEMBL9959991 0.65 IDO1 (0.39)
SCHEMBL4511998 0.64 IDO1 (0.30)
SCHEMBL17766690 0.60 GSK3A (0.36)
SCHEMBL4514508 0.60 IDO1 (0.30)
SCHEMBL4499393 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006124544-A2 USE OF TYROSINE KINASE INHIBITORS IN THE TREATMENT OF METABOLIC DISORDERS NOVARTIS AG (CH) 2006-11-23 WO disclosed
EP-1631291-A2 USE OF TYROSINE KINASE INHIBITORS TO TREAT DIABETES Hägerkvist, Robert P. (SE) 2006-03-08 EP disclosed
WO-2004105763-A2 USE OF TYROSINE KINASE INHIBITOR TO TREAT DIABETES HAEGERKVIST ROBERT PER (SE) 2004-12-09 WO disclosed